When Hodgkin lymphoma returns or resists treatment: reassessment, salvage therapy, and transplantation

Hearing that Hodgkin lymphoma has returned or resisted treatment can make the effort of the first course feel wasted. These terms mean that the disease needs a fresh assessment; they do not automatically mean that no further pathway exists. For classical Hodgkin lymphoma, subsequent care may involve medicines, transplantation in suitable circumstances, and selected local radiation. The sequence depends heavily on treatment already received.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

When a new finding will lead to a major treatment change, the team will usually consider tissue confirmation that the disease is still classical Hodgkin lymphoma. A new mass after a long interval should not be assumed to represent the original disease solely because of the patient's history. The safest accessible site and the feasibility of biopsy require clinical assessment.[S2]
Autologous transplantation uses the patient's own blood-forming cells to support recovery after high-dose treatment. It does not replace the immune system with a donor's, and the reinfusion alone is not the entire procedure. Collection, conditioning, low blood counts, infection management, and recovery form a connected course that requires a transplant service.[S14][S35]
A referral should make clear whether recurrence is confirmed, how quickly disease is changing, which BV or PD-1 drugs were used, and whether a transplant assessment already exists. These details help the hospital coordinate hematology, pathology, and transplant appointments. If severe symptoms are present, obtain local stabilization rather than waiting for visas and transport to be completed.

Quick answer

Full guide

Begin by establishing what has happened. Primary refractory disease, early progression after treatment, a later relapse, and an isolated suspicious scan are not interchangeable situations. Put the dates and supporting findings in order. This helps prevent an uncertain imaging result from being treated as a confirmed recurrence before the diagnostic question has been resolved.

Why another biopsy may be important

When a new finding will lead to a major treatment change, the team will usually consider tissue confirmation that the disease is still classical Hodgkin lymphoma. A new mass after a long interval should not be assumed to represent the original disease solely because of the patient's history. The safest accessible site and the feasibility of biopsy require clinical assessment.[S2]

Provide the original and current pathology material for comparison when possible. Different wording on two reports may need review by a hematopathologist rather than interpretation of one stain by the family. If the sample is inadequate, ask which question remains unanswered and how it will be resolved. An uncertain report should remain identified as uncertain; it should not be converted into a definite diagnosis simply to move an administrative treatment plan forward.

Clarify what an abnormal PET result means

PET findings are interpreted with baseline images, treatment timing, symptoms, and possible infection. Changes during or after immunotherapy can require particular care. Do not stop treatment independently because uptake has increased, and do not assume that every abnormality is a benign immune response. Both approaches can miss the clinical question that the scan is meant to answer.[S28]

If the recommendation is to reassess before changing treatment, ask for the medical reason, the intended timing, and the developments that should trigger earlier contact. If immediate salvage therapy is recommended, ask what establishes progression sufficiently to act. Understanding the rationale helps a patient distinguish purposeful reassessment from unexplained delay, without treating speed alone as a measure of the quality of care.

Construct a timeline of actual treatment

List each regimen, cycles actually delivered, best response, reason for stopping, and the date disease returned or progressed. Include previous BV or PD-1 treatment, radiation fields, and any autologous transplant. “Had chemotherapy that did not work” leaves the receiving team without the information needed to choose a different approach.

Add unresolved toxicities, such as neuropathy, cardiac dysfunction, lung injury, or an immune-mediated complication. Later treatment cannot be selected simply by finding a new drug name; cumulative harm matters. A medicine stopped because of toxicity is a different exposure history from one that failed to control lymphoma. Accurate documentation helps the team judge whether another use would be reasonable or whether a different class is needed.[S37][S38]

Agree on the destination of salvage treatment

For a patient suitable for autologous transplantation, salvage therapy commonly aims to establish good disease control before high-dose treatment and stem cell rescue. Someone who is temporarily or permanently unsuitable for transplant may follow a drug-control, symptom-focused, or research pathway. The main objective should be discussed before starting the next regimen rather than postponed until several cycles have been given.[S14]

Transplant eligibility is not determined by age alone. Organ function, infection, physical reserve, previous exposure, and current disease response require evaluation. Some barriers can be treated and reassessed; others change the overall strategy. Ask which issue presently limits eligibility and whether there is a realistic condition under which the decision could be reviewed. This turns a broad statement of ineligibility into information that can guide care.

No salvage regimen is best without a clinical context

Platinum- or gemcitabine-containing chemotherapy, BV-based combinations, and PD-1 approaches can appear in different salvage pathways. Selection considers earlier treatment and tolerable toxicity. A patient need not memorize every acronym, but should understand why the proposed regimen fits and what response will be needed to proceed to the intended next step.[S1]

A phase II study of pembrolizumab with GVD showed substantial activity in selected transplant-eligible patients after first-line therapy and enabled many to proceed to transplantation. It was a defined, single-arm study with a subsequent treatment plan. Its results should not become a guarantee for every relapsed patient, nor should the transplant component be removed simply because the pretransplant response looks encouraging.[S49]

When the first salvage approach is insufficient

An assessment that falls short of the intended response prompts another review. The options may include a different drug class, a local intervention, or revision of the transplant strategy. Continuing the same treatment and switching can each have a rationale, but neither should occur indefinitely without a reassessment point. Ask when the next evaluation will occur and what the plan is if control remains inadequate.[S2]

For a second opinion, provide the full images and the clinical interpretation. A message stating only that complete remission was not achieved loses information about the amount of residual disease, whether it is still shrinking, and whether new sites have appeared. Where timing is tight, advance record review may reduce delays after arrival. The new team still needs adequate evidence before making a major treatment change.

What autologous transplantation contributes

Autologous transplantation uses the patient's own blood-forming cells to support recovery after high-dose treatment. It does not replace the immune system with a donor's, and the reinfusion alone is not the entire procedure. Collection, conditioning, low blood counts, infection management, and recovery form a connected course that requires a transplant service.[S14][S35]

Before proceeding, the team needs to establish that collection is adequate and that infection and organ status permit the next stage. A date for stem cell return cannot determine a flight booking. Hospital discharge, leaving the area near the transplant center, and resuming international travel may be separate decisions. Ask what medical criteria and local support are required at each transition, rather than relying on a general estimate of the length of admission.

Consider post-transplant consolidation individually

AETHERA supports BV consolidation after autologous transplantation for patients with specified risk factors for relapse or progression. It does not mean that every transplant recipient must receive BV afterward. Earlier exposure is especially relevant now that some patients receive the drug sooner, and persistent neuropathy can affect the benefit-risk discussion.[S48]

If consolidation is proposed, ask for the evidence relevant to the person's risk profile, the planned course, stopping rules, and toxicity monitoring. If it is not proposed, the reason can also be explained. Additional treatment during remission should have a defined purpose; the idea that more therapy must always provide extra insurance is not an adequate basis for prescribing it.

After autologous transplant failure or when transplant is unsuitable

PD-1 inhibitors, BV, and other appropriate approaches may still be considered. KEYNOTE-204 provides randomized evidence comparing pembrolizumab with BV in patients who had relapsed after autologous transplantation or were ineligible for it. Previous exposure, organ function, and the present objective remain important when applying those results.[S26]

Selected patients may discuss allogeneic transplantation. This introduces a donor and distinct immune complications, including graft-versus-host disease, so it should not be described as another version of the same autologous procedure. Prior PD-1 treatment also affects transplant planning. Transfer the exact last-dose date and details of immune complications. The transplant physicians should determine the timing and precautions rather than asking the patient to apply an interval found online.[S2]

Where radiation can fit

A limited lesion, selected residual disease, or a region causing pain or compression may justify radiation assessment. The timing in relation to transplant and the possibility of treating a previously irradiated area depend on disease control, prior dose, and nearby organ tolerance. Radiation is not a universal stand-alone solution for systemic relapse.[S40]

Bring earlier radiation plans and dose records to the consultation. Ask the lymphoma and radiation teams to explain the objective together. Improvement in a local symptom can be valuable, but local control and systemic response are different outcomes. Clarify which medicines or assessments still remain after the symptom improves. Otherwise, a patient may mistakenly regard relief of pain as completion of the entire relapse treatment plan.

Complications can alter the sequence

After repeated therapy, fever, shaking chills, breathing difficulty, or a change in alertness needs prompt assessment. Low blood counts and infection can affect subsequent dosing and stem cell collection. Do not conceal symptoms to preserve a transplant booking. Discharge instructions should specify where to seek urgent care and how to contact the responsible service.[S9]

Following PD-1 treatment, ongoing diarrhea, cough, jaundice, or endocrine symptoms can also require evaluation for immune toxicity. Record any steroids or other immunosuppressive treatment, including changes and the current status. Improving lymphoma scans and unresolved complications can occur at the same time. The next stage must address both, rather than using tumor response alone as proof that the body is ready.[S37]

Discuss research while choices remain available

A trial may study a new combination, cell treatment, or a different way to connect treatment stages. Eligibility can depend on exact pathology, previous drugs, organ function, and other criteria. A registry marked as recruiting does not establish an available place at a specific center. Before starting another therapy, ask whether a relevant study should be considered, because a new exposure can sometimes alter eligibility.[S18][S19]

For any proposed study, establish what the research covers, what remains chargeable, how long visits may be needed, and how treatment continues if the participant withdraws. An investigational option should not delay stabilization of urgent illness. Potential benefit and uncertainty belong in the consent discussion; selected success stories cannot replace the protocol or the investigator's explanation of risk.

Coordinate salvage care in China before travel

A referral should make clear whether recurrence is confirmed, how quickly disease is changing, which BV or PD-1 drugs were used, and whether a transplant assessment already exists. These details help the hospital coordinate hematology, pathology, and transplant appointments. If severe symptoms are present, obtain local stabilization rather than waiting for visas and transport to be completed.

Chinese indications should be checked against current regulatory and prescribing information. The NHC's 2025 edition provides a dated reference, while later updates, hospital stock, and trial places require separate confirmation. Request an itemized RMB budget for diagnostic reassessment, salvage medicines, collection and transplant evaluation, admission, complication management, and subsequent follow-up. Amounts not formally quoted should remain unconfirmed.[S7][S12]

The relapse consultation can center on a concise question: what next step are we trying to reach, and what result would let us proceed? A named clinician, a response criterion, and an alternative plan for each stage make the pathway easier to follow. They do not remove uncertainty, but they let the patient understand which problem is being addressed now and what information will guide the decision after it.